MarketPulse

Keytruda

6 articles
BenzingaBenzinga··Vandana Singh

Merck Reports Q1 Loss on Cidara Acquisition Charge, But Beats on Sales Growth

Merck posts Q1 loss on Cidara acquisition charge but beats revenue expectations with 5% sales growth, raises 2026 guidance.
MRKKeytrudaQ1 2026 earnings
BenzingaBenzinga··Vandana Singh

Merck Tumbles 4% as Cancer Trial Fails, Though HIV Approval Offers Lifeline

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.
MRKEXELFDA approvalclinical trial failure
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novartis Edges Out Merck as Superior Pharma Dividend Play

Novartis offers better dividend yields and diversification than Merck, with stronger long-term prospects despite both beating the S&P 500.
MRKNVSdividend stocksdividend yield
BenzingaBenzinga··Tanya Rawat

Merck to Acquire Terns Pharma for $6B, Bolstering Oncology Pipeline Before Keytruda Patent Cliff

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.
MRKNVSTERNacquisitionM&A
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lilly's Valuation Trap vs. Merck's Dividend Appeal: A Tale of Two Pharma Giants

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.
MRKLLYvaluationdividend stocks
BenzingaBenzinga··Vandana Singh

Merck Restructures Commercial Operations Ahead of Keytruda Patent Cliff

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.
MRKrestructuringpatent expiration